Centro de Investigaciones Biológicas Margarita Salas, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain.
Blood. 2021 Dec 2;138(22):2185-2201. doi: 10.1182/blood.2021012037.
Atypical hemolytic uremic syndrome (aHUS) is a life-threatening thrombotic microangiopathy that can progress, when untreated, to end-stage renal disease. Most frequently, aHUS is caused by complement dysregulation due to pathogenic variants in genes that encode complement components and regulators. Among these genes, the factor H (FH) gene, CFH, presents with the highest frequency (15% to 20%) of variants and is associated with the poorest prognosis. Correct classification of CFH variants as pathogenic or benign is essential to clinical care but remains challenging owing to the dearth of functional studies. As a result, significant numbers of variants are reported as variants of uncertain significance. To address this knowledge gap, we expressed and functionally characterized 105 aHUS-associated FH variants. All FH variants were categorized as pathogenic or benign and, for each, we fully documented the nature of the pathogenicity. Twenty-six previously characterized FH variants were used as controls to validate and confirm the robustness of the functional assays used. Of the remaining 79 uncharacterized variants, only 29 (36.7%) alter FH expression or function in vitro and, therefore, are proposed to be pathogenic. We show that rarity in control databases is not informative for variant classification, and we identify important limitations in applying prediction algorithms to FH variants. Based on structural and functional data, we suggest ways to circumvent these difficulties and, thereby, improve variant classification. Our work highlights the need for functional assays to interpret FH variants accurately if clinical care of patients with aHUS is to be individualized and optimized.
非典型溶血性尿毒症综合征 (aHUS) 是一种危及生命的血栓性微血管病,如果不治疗,可进展为终末期肾病。最常见的是,由于编码补体成分和调节剂的基因突变导致补体失调引起 aHUS。在这些基因中,因子 H (FH) 基因、CFH 出现变异的频率最高(15% 至 20%),且与预后最差相关。正确分类 CFH 变异是致病性的还是良性的对于临床护理至关重要,但由于缺乏功能研究,仍然具有挑战性。因此,大量的变异被报告为意义不明的变异。为了解决这一知识空白,我们表达并对 105 种与 aHUS 相关的 FH 变异进行了功能特征分析。所有 FH 变异均被归类为致病性或良性,并且为每种变异都充分记录了致病性的性质。26 种先前表征的 FH 变异用作对照,以验证和确认所使用的功能测定的稳健性。在剩余的 79 种未表征的变异中,只有 29 种(36.7%)在体外改变 FH 的表达或功能,因此被认为是致病性的。我们表明,在对照数据库中罕见并不能为变异分类提供信息,并且我们确定了将预测算法应用于 FH 变异的重要局限性。基于结构和功能数据,我们提出了克服这些困难的方法,从而改善了变异分类。我们的工作强调了需要进行功能测定来准确解释 FH 变异,如果要对 aHUS 患者进行个体化和优化的临床护理。